Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 100%High 0 · 0%

Co‐formulated abacavir‐lamivudine‐zidovudine vs NNRTIs or PIs

Virologic failure 2 successive HIV‐1 RNA >= 200copies/ml at 16+ weeks after randomisation · patients with initial treatment of HIV infection in antiretroviral‐naive individuals

Co‐formulated abacavir‐lamivudine‐zidovudine showed no clear difference in virologic failure 2 successive HIV‐1 RNA >= 200copies/ml at 16+… compared with NNRTIs or PIs (moderate certainty).

1 finding from 1 review

Co‐formulated abacavir‐lamivudine‐zidovudine for initial treatment of HIV infection and AIDS 2013 · Cochrane Headline outcomes only
RR 1.14 [0.56, 2.31]
3 studies · 1687 participants
Moderate

Co‐formulated abacavir‐lamivudine‐zidovudine vs NNRTIs or PIs

Virologic suppression Viral load < 50 copies/ml · patients with initial treatment of HIV infection in antiretroviral‐naive individuals

Co‐formulated abacavir‐lamivudine‐zidovudine showed no clear difference in virologic suppression Viral load < 50 copies/ml compared with NNRTIs or PIs (moderate certainty).

1 finding from 1 review

Co‐formulated abacavir‐lamivudine‐zidovudine for initial treatment of HIV infection and AIDS 2013 · Cochrane Headline outcomes only
RR 0.97 [0.75, 1.25]
4 studies · 2247 participants
Moderate

Co‐formulated abacavir‐lamivudine‐zidovudine vs NNRTIs or PIs

CD4 cell count · patients with initial treatment of HIV infection in antiretroviral‐naive individuals

1 finding from 1 review

Co‐formulated abacavir‐lamivudine‐zidovudine for initial treatment of HIV infection and AIDS 2013 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1687 participants
Moderate

Co‐formulated abacavir‐lamivudine‐zidovudine vs NNRTIs or PIs

Severe adverse events · patients with initial treatment of HIV infection in antiretroviral‐naive individuals

Co‐formulated abacavir‐lamivudine‐zidovudine showed no clear difference in severe adverse events compared with NNRTIs or PIs (moderate certainty).

1 finding from 1 review

Co‐formulated abacavir‐lamivudine‐zidovudine for initial treatment of HIV infection and AIDS 2013 · Cochrane Headline outcomes only
RR 1.22 [0.78, 1.92]
4 studies · 2247 participants
Moderate

Co‐formulated abacavir‐lamivudine‐zidovudine vs NNRTIs or PIs

Hypersensitivity · patients with initial treatment of HIV infection in antiretroviral‐naive individuals

Co‐formulated abacavir‐lamivudine‐zidovudine showed no clear difference in hypersensitivity reactions compared with NNRTIs or PIs (moderate certainty).

1 finding from 1 review

Co‐formulated abacavir‐lamivudine‐zidovudine for initial treatment of HIV infection and AIDS 2013 · Cochrane Headline outcomes only
RR 4.04 [0.41, 40.02]
4 studies · 2247 participants
Moderate